[KDIGO 2021 guideline glomerulonephritis - focus on ANCA-associated vasculitides and anti-glomerular basement membrane glomerulonephritis]. / KDIGO-Leitlinien 2021 zur Glomerulonephritis Focus ANCA-assoziierte Vaskulitiden und antiglomeruläre Basalmembran-Nephritis.
Dtsch Med Wochenschr
; 146(23): 1552-1558, 2021 11.
Article
em De
| MEDLINE
| ID: mdl-34826843
ABSTRACT
In 2021 new KDIGO (Kidney Disease Improving Global Outcomes) guidelines for the management of glomerular diseases were published.For ANCA-associated glomerulonephritis the new recommendations comprise a more rapid steroid taper during induction treatment with cyclophosphamide or rituximab, the advice against routine use of plasma exchange, the choice of drug for and duration of maintenance treatment in accordance with predictors of relapse. A kidney transplant should be performed after at least 6 months of remission irrespective of the ANCA titer in ANCA-associated disease, and 6 months after absence of anti-GBM-antibodies in anti-GBM-disease.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doença Antimembrana Basal Glomerular
/
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos
Tipo de estudo:
Guideline
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
De
Ano de publicação:
2021
Tipo de documento:
Article